The medical laboratory is a prevention player: every blood draw is an opportunity to identify a risk, and Article L6211-8 of the French Public Health Code allows the laboratory physician (biologiste médical) to adapt the prescription when they consider it appropriate. A questionnaire at the laboratory, written rules and a strong link with the doctor turn this into a relevant pathway, without overprescribing.
What role does a medical laboratory play in prevention?
The laboratory is one of the few places where a patient without symptoms shows up, with some waiting time and a sample already taken. The laboratory physician, who in France may be a pharmacist or a medical doctor by training, carries medical responsibility there: they validate every result, interpret it and can supplement the prescription. That is what makes the laboratory a link in the prevention chain.
Prevention takes three forms there. First, secondary prevention: detecting an abnormality before symptoms appear (blood sugar, lipid panel, serology tests). Next, primary prevention, through advice when results are delivered: a result explained by the laboratory physician is an opportunity to discuss smoking, diet or physical activity. Finally, quaternary prevention, less visible but essential: not performing a test that serves no purpose, avoiding false positives and cascades of further investigations. These four types of prevention are defined in our glossary.
The economic framework matters. Laboratory tests coded under the “B” key letter are reimbursed at 60% of the French National Health Insurance (Assurance Maladie) rate with a prescription, at 70% for anatomical and cytological pathology, and at 100% for HIV and hepatitis C serology screening (ameli.fr, general scheme). A test requested without a prescription is paid by the patient. Ballpark costs for a blood test without a prescription are given in our article on the comprehensive blood test.
What exactly does Article L6211-8 of the French Public Health Code allow?
Article L6211-8 allows the laboratory physician, when they consider it appropriate, to perform tests that are not on the prescription or not to perform all of those that are, in compliance with good practice guidelines and the nomenclature, unless the prescriber has objected on the prescription. It is a regulated power to adapt, not a right to prescribe freely.
The text, in the version in force since January 1, 2021
“A medical laboratory test is performed on the basis of a prescription that contains the relevant clinical information.
When they consider it appropriate, the laboratory physician performs, in accordance with the good practice guidelines referred to in Article L. 161-37 of the Social Security Code where they exist and in compliance with the nomenclature of medical laboratory procedures established pursuant to Article L. 162-1-7 of the same code, medical laboratory tests other than those appearing on the prescription, or does not perform all the tests that appear on it, unless the prescriber has indicated otherwise on the prescription.”
This wording results from Article 94 of Law No. 2020-1525 of December 7, 2020, known as the ASAP law. The previous version required any change to be proposed to the prescriber, except in an emergency or if the prescriber was unavailable; the current text places the decision with the laboratory physician, subject to cumulative conditions.
The conditions set by the text
| Condition set by L6211-8 | What it means at the laboratory |
|---|---|
| A prescription “that contains the relevant clinical information” | Adaptation starts from a prescription; the questionnaire and the conversation supplement the clinical information, they do not replace the prescription |
| “When they consider it appropriate” | An individual medical decision by the laboratory physician, traceable and justified by the patient’s context |
| Compliance with HAS (French National Authority for Health) good practice guidelines “where they exist” | The laboratory’s add-on rules rely on cited guidelines; no “just in case” additions |
| Compliance with the nomenclature of medical laboratory procedures (NABM) | Only listed tests, and only under their coverage conditions; anything else is off-nomenclature and not reimbursed |
| “Unless the prescriber has indicated otherwise on the prescription” | The doctor stays in control: a note on the prescription blocks any change |
Two limits are worth stating. The article does not create a right to prescribe for a patient who comes without a prescription: in that case, the laboratory performs the requested test, not reimbursed, or refers the patient to a doctor. And it does not exempt the laboratory from informing the prescriber: good practice is to mention the addition and its justification in the report.
Why does a questionnaire at the laboratory change the value of the sample?
Because the prescription says almost nothing about the patient. A prescription for “CBC, blood sugar, lipid panel” says nothing about smoking, family history, weight, alcohol or sleep. A short questionnaire, filled in in the waiting room on the patient’s phone, gives the laboratory physician this clinical information at the moment the tube is drawn, and lets them use the power granted by Article L6211-8 on an informed basis rather than blindly.
Three conditions make this questionnaire acceptable and useful. It is offered, never imposed: the patient can decline with no consequence for their tests. It is transparent: the patient knows what their answers are used for (decision support, test suggestion, possible out-of-pocket cost). It is covered by confidentiality: the answers are health data, stored with a certified health data host (HDS), accessible to the laboratory physician and, with the patient’s consent, to the prescriber; never to a third party.
About ten questions targeting what changes a laboratory decision (age, smoking, family history, weight, blood pressure, alcohol, medications, pregnancy, recent symptoms) are enough; beyond that, completion rates drop.
Which additional tests are relevant, and how do you avoid overprescribing?
An additional test is relevant if it responds to an identified risk, if a guideline recommends it in that situation, if it is listed in the nomenclature and if it has a practical consequence for the patient. When any of these conditions is missing, it is not added.
| Situation identified by the questionnaire | Test to consider (on the same sample) | Reference to cite in the add-on rule |
|---|---|---|
| Adult over 45 with at least one risk factor (excess weight, family history, high blood pressure) | Fasting blood sugar if not on the prescription | HAS guideline on type 2 diabetes screening |
| Smoking, family history of cardiovascular disease, known high blood pressure | Full lipid panel (total cholesterol, HDL, LDL, triglycerides, non-HDL) if incomplete | 2021 ESC guidelines on cardiovascular prevention; SCORE2 calculation |
| Known diabetes or high blood pressure | Creatinine with estimated glomerular filtration rate; albuminuria test | HAS guidelines on chronic kidney disease |
| Reported alcohol consumption above the guideline limits | Transaminases, gamma-GT if not prescribed | Santé publique France (the French public health agency) drinking guidelines; HAS guidelines |
| Reported sexual risk exposure | HIV and hepatitis C serology screening (fully covered, 100%) | ameli.fr (100% rate); HAS screening guideline |
| Fatigue, heavy periods, vegan diet | Ferritin, vitamin B12 depending on context | HAS guidelines on iron deficiency |
This table helps write internal rules; each laboratory validates them with its lead laboratory physician and keeps them up to date. Our article on 10-year cardiovascular risk describes the SCORE2 variables.
Safeguards against overprescribing
- No test without a consequence. If the result will change neither advice, nor a referral, nor a treatment, it has no place.
- No test outside guidelines in the general population. “Out of curiosity” tests (multiple vitamins, hormones without symptoms, tumor markers used for screening) produce false positives and unnecessary investigations; the HAS regularly publishes appropriateness opinions that remove tests from routine practice.
- No off-nomenclature test presented as reimbursed. The patient is informed of the out-of-pocket cost before any non-covered test is added.
- A tracked add-on rate. Too high, and the rule is too broad; zero, and the questionnaire serves no purpose. The benchmark is set with the lead laboratory physician.
- A record. Each addition is justified in the laboratory’s system and mentioned in the report.
How do you coordinate the laboratory with the regular doctor?
The doctor remains the linchpin: Article L6211-8 leaves them a right to object on the prescription, and the report goes back to them. A prevention pathway at the laboratory succeeds when prescribers in the area know what the laboratory adds, why, and how they can opt out.
In practice, four habits. Inform prescribers in advance, with a letter describing the add-on rules and the note to write on the prescription to exclude them. Mention in every report the added test, a one-line justification and the guideline. Send results via secure health messaging, under Article L1110-4 of the French Public Health Code, which authorizes the exchange of information between professionals involved in the patient’s care, limited to what is “strictly necessary for the coordination or continuity of care.” Finally, refer patients without a regular doctor (médecin traitant) to a point of access (regular doctor, health center, preventive health examination). For patients with poor access to care, this preventive health examination, fully covered (100%) from age 16, is a useful entry point.
That leaves the question of Mon bilan prévention, France’s national prevention check-up program. The decree of May 28, 2024 (arrêté du 28 mai 2024) designates doctors, midwives, nurses and pharmacists as the professionals who carry out this €30 check-up; a laboratory that employs laboratory physicians from these professions could in principle organize it, in a private consultation area. Until this point is settled, the laboratory remains a relay: it identifies, informs and refers to a professional who carries out the check-up.
What does NMR metabolomics bring to a laboratory?
Nuclear magnetic resonance (NMR) metabolomics quantifies, from a single blood sample, 249 metabolic biomarkers (lipoproteins by class and size, fatty acids, amino acids, glycolysis markers, ketone bodies, the inflammation marker GlycA), described in 118,461 UK Biobank participants (Julkunen et al., 2023). It considerably broadens what can be read from a sample already taken; it does not make a diagnosis and it is not a reimbursed test.
What the publications show: in 117,981 UK Biobank participants, a profile of 168 NMR markers improves the prediction of 10-year risk for 24 diseases, beyond conventional risk factors, with validation in four independent cohorts (Buergel et al., Nature Medicine, 2022). The technology relies on NMR spectroscopy combined with machine learning; its developer, Nightingale Health, states that it has analyzed “more than two million samples.” Conventional scores such as SCORE2 rely on five variables; metabolomics adds dozens. We describe the method and its limits in our article on NMR metabolomics and how the results are used in the one on metabolic age.
For a laboratory, three points call for vigilance. The analysis is performed as an option, on the same sample, after informing the patient of the out-of-pocket cost; it is offered only if the risk profile justifies it. Results are interpreted by a doctor, not handed over raw. Certification claims (ISO 15189, CE marking of tests) and turnaround time are those documented by the laboratory that performs the analysis.
How do you organize a prevention pathway at the laboratory in practice?
A pathway comes down to seven steps, led by a lead laboratory physician. The principle: nothing is added without a written rule, without informing the patient and without a record for the prescriber.
- Appoint a lead laboratory physician and write the add-on rules: situations, tests, guidelines, nomenclature conditions, patient information.
- Inform prescribers in the area: letter, opt-out note, contact details of the lead physician.
- Roll out the questionnaire in the waiting room: offered at reception, filled in on the patient’s phone, option to decline, patient information and certified hosting.
- Validate each addition: the laboratory physician sees the suggestion generated by the questionnaire, accepts, modifies or rejects it; the test is billed according to the nomenclature and the out-of-pocket cost is disclosed.
- Deliver and explain: report with the justification for the addition; laboratory physician’s comment to the patient; secure transmission to the prescriber.
- Refer: patients without a regular doctor, results requiring a consultation, screenings and vaccinations brought up to date.
- Measure: quarterly indicators reviewed with the lead physician.
| Suggested indicator | Type | Why track it |
|---|---|---|
| Share of patients offered the questionnaire, and completion rate | Resources | Measures actual implementation at reception |
| Share of samples with an added test, by rule | Appropriateness | Flags a rule that is too broad or useless |
| Share of additions rejected by the laboratory physician | Quality | The laboratory physician stays in control |
| Share of additions with a justification in the report | Traceability | Good practice requirement |
| Prescriber objections received and handled | Coordination | A warning sign not to ignore |
| Abnormal results with a documented referral | Results | Identification leads to care |
| Average out-of-pocket cost per non-reimbursed addition, and acceptance rate | Ethics | Prevents commercial drift |
What common mistakes should you avoid?
Pathways that go off track share a few traits: unwritten rules, a poorly informed patient, a prescriber kept out of the loop, and confusion between prevention and test volume.
- Confusing L6211-8 with free prescribing. The article adapts an existing prescription; it does not create a right to prescribe for a patient without one.
- Adding tests without a guideline. Each rule cites its guideline and its nomenclature condition; otherwise, it does not exist.
- Forgetting the out-of-pocket cost. An off-nomenclature or non-reimbursed test is disclosed before the sample is taken, not discovered on the bill.
- Keeping the prescriber out of the loop. Without prior information or a justification in the report, doctors’ trust erodes and objections multiply.
- Presenting metabolomics as a diagnosis or a reimbursed test. It is an optional risk estimate, interpreted by a doctor and paid by the patient.
- Treating questionnaire answers as ordinary data. They are health data: certified host, restricted access, patient information. Our commitments are described on the security and data page.
- Ignoring patients without a regular doctor. An abnormal result with no one to follow up is a missed opportunity; referral is part of the pathway, for example in connection with a health center in the area.
Key takeaways
- Article L6211-8 (version in force since January 1, 2021) allows the laboratory physician to adapt the prescription when they consider it appropriate, in compliance with HAS guidelines and the nomenclature, unless the prescriber has indicated otherwise on the prescription.
- A questionnaire offered in the waiting room provides the clinical information missing from the prescription; it is optional, transparent and covered by confidentiality.
- An additional test is relevant only if it responds to an identified risk, is backed by a guideline, is listed in the nomenclature and has a consequence for the patient.
- The doctor remains the linchpin: prior information, justification in the report, secure transmission, referral of patients with no follow-up.
- NMR metabolomics (249 biomarkers) broadens what can be read from the sample as an option, with medical interpretation, without reimbursement and without making a diagnosis.
How to organize this pathway with Sokrate
Biokrate, Sokrate’s service for laboratories, offers patients a questionnaire of a few minutes in the waiting room, on their phone, then shows the laboratory physician the additional tests that are relevant given the reported risk factors, with the associated reference, for the same sample. The laboratory physician validates, modifies or rejects each suggestion under Article L6211-8; the prescriber’s request is enriched, never bypassed, and the patient does not have to come back. As an option, when the profile justifies it, the same sample can give access to an NMR metabolomics analysis of 249 biomarkers, interpreted by a doctor. Learn more on our page for laboratories; to become a partner laboratory or request a demo, contact us.